GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spruce Biosciences Inc (NAS:SPRB) » Definitions » Gross Profit

Spruce Biosciences (Spruce Biosciences) Gross Profit : $10.13 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Spruce Biosciences Gross Profit?

Spruce Biosciences's gross profit for the three months ended in Mar. 2024 was $2.00 Mil. Spruce Biosciences's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $10.13 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Spruce Biosciences's gross profit for the three months ended in Mar. 2024 was $2.00 Mil. Spruce Biosciences's Revenue for the three months ended in Mar. 2024 was $2.00 Mil. Therefore, Spruce Biosciences's Gross Margin % for the quarter that ended in Mar. 2024 was N/A%.

Spruce Biosciences had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Spruce Biosciences Gross Profit Historical Data

The historical data trend for Spruce Biosciences's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spruce Biosciences Gross Profit Chart

Spruce Biosciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial - - - - 10.09

Spruce Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.96 2.17 3.07 2.89 2.00

Competitive Comparison of Spruce Biosciences's Gross Profit

For the Biotechnology subindustry, Spruce Biosciences's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spruce Biosciences's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spruce Biosciences's Gross Profit distribution charts can be found below:

* The bar in red indicates where Spruce Biosciences's Gross Profit falls into.



Spruce Biosciences Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Spruce Biosciences's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=10.089 - 0
=10.09

Spruce Biosciences's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=2.002 - 0
=2.00

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.13 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Spruce Biosciences's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=2.00 / 2.002
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Spruce Biosciences  (NAS:SPRB) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Spruce Biosciences had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


Spruce Biosciences Gross Profit Related Terms

Thank you for viewing the detailed overview of Spruce Biosciences's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Spruce Biosciences (Spruce Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
611 Gateway Boulevard, Suite 740, South San Francisco, CA, USA, 94080
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
Executives
Percival Barretto-ko director 611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO CA 94080
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Niall O'donnell director C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105
Charlton Ralph William Iii officer: Chief Medical Officer 2001 JUNIPERO SERRA BOULEVARD, SUITE 640, DALY CITY CA 94104
Javier B. Szwarcberg director, officer: Chief Executive Officer 2001 JUNIPERO SERRA BOULEVARD, SUITE 640, DALY CITY CA 94014
Kirk Ways director C/O 2001 JUNIPERO SERRA BOULEVARD, SUITE 540, DALY CITY CA 94014
Camilla V Simpson director 20 ELAINE AVE., MILL VALLEY CA 94941
Bali Muralidhar director C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077
Jonas Hansson director 18 AVENUE D'OUCHY, LAUSANNE V8 CH-1006
Rivervest Venture Fund Iii (ohio), L.p. 10 percent owner 11000 CEDAR AVENUE, SUITE 100, CLEVELAND OH 44106-3502
Healthcap Viii, L.p. 10 percent owner 18 AVENUE D'OUCHY, C/O HEALTHCAP VIII GP SA, CH 1006 LAUSANNE V8 1006
Moghrabi Dina Chaya director 22 GLEDHOW GARDENS, FLAT 2, LONDON X0 SW5 0AZ
Omega Fund Vi Gp Manager, Ltd. 10 percent owner 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Samir M. Gharib officer: Chief Financial Officer 2655 PINE STREET, #6, SAN FRANCISCO CA 94115
Richard King director, officer: Chief Executive Officer C/O KOS PHARMACEUTICALS INC, 1001 BRICKELL AVE 25TH FL, MIAMI FL 33131